Histone deacetylases (HDACs) are histone-modifying enzymes associated with several cell mechanisms, and of note, the transcriptional regulation of tumor repressor genes. They have been extensively considered as a target in drug discovery for cancer therapy leading to the development of small molecules as catalytic HDAC inhibitors. 1 Although transcriptional regulation is one of the mechanisms involved in the efficacy of HDAC inhibitors, part of the mode of action of pan-inhibitors has been associated with the catalytic inhibition of HDAC6, a cytosolic isoform. The role of HDAC6
in the clearance of misfolded proteins is of particular interest. Upon proteasome impairment, ubiquitin (Ub)-conjugated protein aggregates are recruited by HDAC6, as a compensatory pathway of elimination. 2, 3 The combination of proteasome inhibitors with HDAC6 catalytic inhibitors has been proven to be effective in multiple myeloma, encouraging the development of deacetylase inhibitors selective to HDAC6 for clinical applications. [2] [3] [4] HDAC6 is particular in the fact that it possesses two catalytic deacetylase domains (CD1 and CD2) and a C-terminal zinc-finger Ub-binding domain (ZnF-UBP) 5 ( Fig. 1a) . Strong evidence suggests that intact CD1, CD2, and ZnF-UBP domains play a role in regulating aggresome formation and clearance by HDAC6, 6, 7 with speculations on a possible decrease in HDAC6-Ub interaction upon treatment with the selective HDAC6 inhibitor tubastatin A. 8 Nevertheless, the mechanisms on how catalytic inhibitors of HDAC6 might modulate this specific interaction remained unclear until now. One hypothesis is that the catalytic inhibition would ultimately promote HDAC6 cell de-localization, changing the HDAC6 protein-protein interaction (PPI) profile. Another hypothesis is that the binding of small molecules to the catalytic domains of HDAC6 would promote conformational changes resulting in the disruption of the interaction between HDAC6 ZnF-UBP and Ub. The latter can only be assessed by cell-free protein interaction assays using full-length HDAC6. Up to now, a diversity of binding methods using the HDAC6 ZnF-UBP domain alone have been considered to address the modulation of the HDAC6-Ub interaction. 9, 10 However, they are not suitable for investigating the implications of the catalytic deacetylase domains in the HDAC6-Ub interaction. Here we describe two in vitro methods allowing 1) to evaluate the interplay between catalytic domains and the ZnF-UBP in HDAC6, and 2) to retrieve small molecules interacting with the ZnF-UBP leading to HDAC6-Ub PPI inhibition.
Results and discussion
First, we adapted a microscale thermophoresis (MST) method, using human full-length HDAC6, to detect the specific binding of proteins and small drug-like molecules to the HDAC6 ZnF-UBP domain. MST is a fluorescence-based technique with a wide range of applications in the study of biomolecular interactions. Binding of molecules to a fluorescent partner will impact its thermophoretic behavior due to changes in the hydration shell, size, and charge upon binding. In addition, the method can be used to evaluate changes in the temperature jump (T-Jump), which are triggered when binding occurs close to the fluorophore environment. Another advantage of MST is the fact that proteins can be expressed in cells directly as fusion fluorescent proteins, avoiding subsequent labeling chemistry or immobilization steps that may be deleterious to protein folding and activity. 11 As a matter of fact, we have previously experienced loss of binding activity of the fulllength HDAC6 while attempting amino coupling reactions for labeling (in MST approach) or immobilization on surface plasmon resonance (SPR) supports (data not shown).
To provide suitable fluorescent interaction partners, HEK 293 cells were transiently transfected with full-length HDAC6-EGFP constructs to obtain the wild type (HDAC6-EGFP WT), the catalytic deficient (HDAC6-EGFP CD), and the ZnF-UBP deleted (HDAC6-EGFP ΔZnF-UBP) proteins, separately (Fig. 1a,b) . In all these constructs, EGFP was fused to HDAC6 C-terminus, which is closely located to ZnF-UBP. Then, MST experiments were conducted with the whole cell lysates to increase HDAC6 folding stability and maintain its catalytic activity at the same time (Fig. S1 ).
HDAC6-Ub binding curves using lysates containing HDAC6-EGFP WT, CD, and ΔZnF-UBP proteins were obtained by evaluating thermophoresis + T-Jump (Fig. 1c) . The dissociation constant interference by endogenous free Ub, Ub-chains, or Ub-like proteins (Fig. S2) . The K D for His-tag Ub binding to HDAC6 was in accordance with previously published ITC data using the ZnF-UBP domain alone 12 ( Fig. S3) . HDAC6 mutations H216A/H611A leading to total catalytic impairment (HDAC6-EGFP CD) resulted in absence of the HDAC6-Ub interaction (Fig. 1c) , suggesting that structural changes in the catalytic domains directly affect the Ub-binding activity of HDAC6. Binding studies with Ub-chains and Ub-like proteins (Fig. S4-5) were also conducted to confirm the versatility of the method and its application in determining affinity constants of PPI in vitro.
A second important application of the method is the screening of small molecules able to interact with HDAC6 residues involved in Ub recognition and potentially acting as direct PPI inhibitors. To demonstrate this application, a structure based virtual screening (SBVS) was first conducted to identify potential compounds targeting the HDAC6 ZnF-UBP. 9, 13 From a chemical library of 197,477 compounds (www.specs.net, SC_specs_10 mg_May2013), 40 potential hits (Table S1 ) were selected and tested by MST for their binding to HDAC6-EGFP WT using thermophoresis + T-Jump (Fig. 2a) .
This measurement provided a suitable Z-factor (0.6) for medium throughput screening and included the contribution of the ZnF-UBP binding via T-Jump. Given the absence of small drug-like molecules able to bind HDAC6 ZnF-UBP or other ZnF-UBP domains, we used 50 µM mono-Ub as a positive binding control for the screening experiments. Therefore, aiming to compare and rank the screened molecules, normalized fraction bound values were determined by comparing the MST curves of the tested compounds to those obtained for the unbound (lysate alone) and bound (lysates pre-incubated with 50 µM mono-Ub) controls. A normalized fraction bound of 0.5 was considered as the threshold resulting in the selection of one hit, compound 16, which had its potential binding mode predicted by molecular docking (Fig. 2b) . MST experiments to determine the K D for the binding between compound 16 and HDAC6-EGFP WT were not possible to be performed considering the selffluorescence displayed by ligand in concentrations higher than 100 µM. In addition to the positive binding control mono-Ub (ZnF-UBP-positive/catalytic-negative), the selective HDAC6 inhibitor tubastatin A (ZnF-UBP-negative/catalytic-positive binding control) and a class I-selective hydroxyl ketone inhibitor (HKI, ZnF-UBP-negative/catalytic-negative binding control, Fig. S6 ) 14 were probed.
Binding of HDAC6 catalytic inhibitors to the full length HDAC6 could be detected in both thermophoresis alone and thermophoresis + T-Jump (Fig. 2c) , but only at a concentration (100 µM)
well above their nanomolar catalytic IC 50 . Moreover, their T-Jump values alone (Fig. 2d) (Fig. 3a) . Concentration-response competition curves were first determined for controls titrated with tag-free mono-Ub (Fig. 3b) . Then, the screening was conducted with the SBVS hits (Fig. 3c) . Compound 16 was confirmed to disrupt the HDAC6-Ub PPI.
Interestingly, tubacin and tubastatin A also inhibited the PPI (Fig. 3c) . Such inhibition corroborates the MST results observed with the catalytic deficient HDAC6. Taken together, these results confirm for the first time that changes in the HDAC6 catalytic domains directly inhibits the HDAC6-Ub PPI, most likely via an allosteric-like mechanism. This was further observed for SAHA, a pan-HDAC inhibitor, to a lesser extent. On the contrary, class I selective inhibitors such as CI-994 and HKI, had no or poor effect on the PPI activity of HDAC6 (Fig. 3c) .
Compound 30 appeared as a second hit in the ELISA-based PPI competition assay, despite the absence interaction by MST measurements. Given that compounds interacting with the catalytic domains, such as tubastatin A and tubacin, were shown to affect HDAC6-Ub interaction, hits 16 and 30 ( Fig. S6) were tested for HDAC6 deacetylase activity. No catalytic inhibition was observed in these assays. However, a 2-fold increase in substrate deacetylation was verified for compound 30 (Table S2) , which opens up the discussion on the mechanisms of HDAC6-Ub inhibition, other than the orthosteric interaction with the HDAC6 ZnF-UBP. residue in the proximal end was removed through reaction with a ubiquitin C-terminal hydrolase (UCH) enzyme. K48-, and K63-linked tetra-Ub chains were later synthesized by successive rounds of deblocking and conjugation.
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Structure-based virtual screening (SBVS)
Specs compounds were prepared for SBVS as previously described 20 . Briefly, the compounds were downloaded from the Specs website (www.specs.net, SC_specs_10 mg_May2013) and protonated at binding poses were generated for each compound. The best-ranked compounds with scores < -8.5
kcal/mol were further filtered for solubility (> 100 µM) and logP (< 5.0), as predicted with VolSurf + version 1.0.7 24 , resulting in 609 compounds that were visually inspected to ensure proper fit to the Ub binding pocket. 80 ligands were selected for re-docking in HDAC6 ZnF-UBP using GOLD version 5.2 (CCDC, Cambridge, UK). The binding site was defined within a 6 Å radius around the co-crystallized peptide. 100 docking poses were generated for each Specs compound, by using 100,000 GOLD Genetic Algorithm interactions (Preset option), and ranked according to the ChemPLP score. Finally, 40 compounds with a ChemPLP score higher than 70 were selected for in vitro binding experiments.
Microscale thermophoresis (MST)
Solutions and serial dilutions of non-tagged mono-Ub, K48-linked di-Ub, and K63-linked di-and performed at room temperature for 30 s at 60% LED power and 40% infrared laser power (Fig. S7) .
For MST experiments with tag-free mono-Ub and Ub chains (Fig. S4) 
HDAC6 catalytic assay
In vitro HDAC6 activity was detected by measuring the fluorophore released from the x g for 10 min. Supernatants were transferred into UHPLC-compatible 96-well plates to be analyzed on a UHPLC-ESI-MS/MS system consisting of an Acquity UPLC System (Waters, Milford, MA, USA) connected to a Quattro Micro triple quadrupole mass spectrometer equipped with an ESI source operating in positive-ion mode (Waters). Deacetylase activity was determined as previously described 25 . Lysates were diluted to result in final EGFP concentrations of 50, 25, and 12.5 nM, corresponding to the concentrations of HDAC6-EGFP fusion proteins used for the MST measurements. Deacetylase activity of recombinant HDAC6 WT (50 U/well, SigmaAldrich) was measured as control in presence and absence of the pan-HDAC inhibitor trichostatin A (300 nM). Lysates of cells expressing HDAC6-ΔZnF-UBP showed a decrease in deacetylase activity in comparison with HDAC6 WT. On the other hand, the deacetylase activity observed for lysates of cells expressing HDAC6 CD is probably due to basal HDAC6 in HEK 293 cells. MST data for mono-ubiquitin and K63-linked polyubiquitin chains binding to EGFP-HDAC6 WT. The observed 2-fold higher affinity measured for K48-and K63-linked di-Ub as well as the 4-fold higher affinity measured for K63-linked tetra-Ub may indicate some DUB activity in the lysates. To address this possibility, we verified the integrity of K48-and K63-linked polyubiquitin after their incubation with lysates of cells expressing the HDAC6-EGFP fusion proteins under the same conditions used in the binding assays. Lysates pre-incubated with 2 µM Ubal (15 min, 37 ºC) were further incubated with (C) 10 µM K48-linked di-Ub (10 min, 37 °C) or (D) 10 µM K48-linked tetra-Ub (10 min, 37 °C), and chain integrity was analyzed by western blot. Lysates pre-incubated with 2 µM Ubal + 2 mM 1,10-phenanthroline or with 1,10-phenanthroline alone (15 min, 37 ºC) were incubated with (E) 10 µM K63-linked di-Ub (10 min, 37 °C) or (F) 10 µM K63-linked tetra-Ub (10 min, 37 °C) and analyzed by western blot. Control experiments were performed with 10 µM mono-Ub or polyubiquitin chains incubated with lysis buffer. These data showed that polyubiquitin chains can be degraded by DUBs present in the lysates even after a preincubation step with DUB inhibitors indicating a drawback for the proposed method. Figure S3 . In summary, we observed that neither mono-ubiquitin or the ubiquitin-like proteins NEDD8 and ISG15 could bind HDAC6-EGFP ΔZnF-UBP (data not shown), confirming that the ZnF-UBP domain is essential for their interactions with HDAC6. In addition, these results support our previous molecular dynamics data suggesting that ubiquitin R42 and R72 may contribute to HDAC6-Ub binding by interacting with HDAC6 E1141 and D1178 4 . 
ELISA-based PPI competition assay
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